epilepsy

Bio & Pharma SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US

South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...

Bio & Pharma SK Biopharm submits NDA of epilepsy drug to China

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Bio & Pharma SK Biopharm targets $311 mn for Cenobamate US sales

South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...

Bio & Pharma SK Biopharm gears up to boost epilepsy drug sales in Europe

SK Biopharmaceuticals Co. is gearing up to explore the European market for its flagship epilepsy drug Cenobamate, while looking for new mergers and ...

Bio & Pharma SK Biopharma’s Cenobamate US patent extended by 2032

South Korea's SK Biopharmaceuticals announced on Friday an extension of its US patent for the epilepsy treatment Cenobamate, now set to expire on Oc...

Bio & Pharma SK Biopharm to export epilepsy drug tech to Middle Eastern firm

South Korea's SK Biopharmaceuticals announced on Friday a strategic tie-up with Hikma MENA FZE, marking the introduction of its new epilepsy medicat...

Bio & Pharma SK Biopharmaceuticals gets OK to sell epilepsy drug in Canada

South Korea's SK Biopharmaceuticals has received approval in Canada to sell its new epilepsy drug Cenobamate under the product name Xcopri. Having e...

Bio & Pharma SK Biopharmaceuticals gets marketing approval for epilepsy drug in Israel

South Korea’s SK Biopharmaceuticals said on Wednesday that the Israeli Ministry of Health has approved the company's new drug application (NDA...

Bio & Pharma SK Biopharm holds sales meeting for marketing Cenobamate in US

On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego. The p...

Bio & Pharma SK Biopharm begins clinical trials of wearable device for detecting epilepsy

SK Group's new drug development subsidiary SK Biopharmaceuticals Co. will begin clinical trials for a wearable device that can detect and predict ep...

Bio & Pharma SK Biopharmaceuticals launches epilepsy drug in France

South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...

Bio & Pharma SK Biopharma's epilepsy treatment posts impressive growth in US

South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medic...

Bio & Pharma SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...

Pharamaceuticals SK Biopharm releases epilepsy treatment in UK

South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europ...

Pharmaceuticals SK Biopharm aims to make it to global top 10 healthcare firms by 2030

South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...